Stuart Lacey

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.

Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.

Journal: The New England journal of medicine

Published: May 13, 2026

Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.

Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 25, 2024

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: June 16, 2021

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.

Journal: The lancet. Gastroenterology & hepatology

Published: June 16, 2021

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

Journal: Advances in therapy

Published: January 31, 2020

Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data.

Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data.

Journal: Rheumatology and therapy

Published: September 03, 2019

Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Journal: Journal of neurovirology

Published: April 11, 2018

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Journal: Journal of neurovirology

Published: November 30, 2017

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.

Journal: Annals of the rheumatic diseases

Published: August 01, 2016

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.

Journal: The Journal of rheumatology

Published: June 17, 2015

Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis.

Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis.

Journal: Annals of the rheumatic diseases

Published: July 31, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026